Tracking antibody dynamics in COVID-19 recovered patients: A longitudinal study at tertiary care hospital in Lahore
DOI:
https://doi.org/10.55629/pakjpathol.v36i2.882Abstract
Objective: To determine the persistence of SARS-CoV-2 IgG antibodies in COVID-19 recovered patients 9 months after recovery.
Material and Methods: It is a longitudinal cohort study which was conducted at Pathology department, tertiary care hospital Lahore. Regardless of age or gender, we measured Anti-SARS-CoV-2 IgG against SARS-COV-2 spike antigen in 250 COVID-19 recovered patients at three distinct time-lines (150-170, 171-220, and 221-270 days) respectively. Those who had reinfection (MA2) or had received vaccination during this time were not included in the study. Semi-quantitative Enzyme Linked Immuno-Sorbent Assay (ELISA) was used to measure the antibodies. Antibody ratio levels of less than 0.8 were regarded as negative, those between 0.8 and 1.1 as borderline, and those greater than 1.1 as positive.
Results: Out of total 250 patients, 88% (220) of the patients were male while 12% (30) were female. Minimum age of study participants was 9 yrs and maximum age was 65 yrs. Mean age of patients was 35 yrs. We found that 151 (68%) of the male study participants and 19 (63%) of the female participants were seropositive at 150 days after COVID-19, whereas 66 (30%) of the male participants and 11 (37%) of female participants were seropositive at 270 days after COVID-19. The percentage of male seropositivity has decreased by 56%, whereas the percentage of female seropositivity has decreased by 41%.
Conclusion: This study has demonstrated that the serological IgG immune response against SARS-CoV-2 showed a diminishing trend after nine months.
Keywords: COVID-19, ELISA, IgG antibodies, SARS-CoV-2
References
Mackenzie JS, Smith DW. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't. Microbiol Aust. 2020: MA20013. DOI: https://doi.org/10.1071/ma20013
Emrani J, Ahmed M, Jeffers-Francis L, Teleha JC, Mowa N, Newman RH, et al. SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. Int J BiolMacromol. 2021; 193(Pt B): 1249-73.
DOI:https://doi.org/10.1016/j.ijbiomac.2021.10.172
Perez-Guzman PN, Knock E, Imai N, et al. Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. Nat Commun. 2023; 14(1): 8099. DOI: https://doi.org/10.1038/s41467-023-44062-9
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel [version 1; peer review: 2 approved]. Wellcome Open Res 2020; 5:139. DOI:https://doi.org/10.12688/wellcomeopenres.15927.1
Dao TL, Hoang VT, Colson P, Lagier JC, Million M, Raoult D, Levasseur A, et al. SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current evidence. J Clin Med. 2021; 10(12): 2635. DOI: https://doi.org/10.3390/jcm10122635
Farshbafnadi M, KamaliZonouzi S, Sabahi M, Dolatshahi M, Aarabi MH. Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors. Exp Gerontol. 2021; 154: 111507. DOI: https://doi.org/10.1016/j.exger.2021.111507
Glynn JR, Moss PAH. Systematic analysis of infectious disease outcomes by age shows lowest severity in school-age children. Sci Data. 2020; 7: 329. DOI: https://doi.org/10.1038/s41597-020-00668-y
Yang K, Wen G, Wang J, Zhou S, Da W, Meng Y, et al. Complication and sequelae of COVID-19: What should we pay attention to in the post-epidemic era. Front Immunol. 2021; 12: 711741. DOI: https://doi.org/10.3389/fimmu.2021.711741
Abebe EC, Dejenie TA. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Front Immunol. 2023; 14: 1055457. DOI: https://doi.org/10.3389/fimmu.2023.1055457
Pons S, Uhel F, Frapy E, Sérémé Y, Zafrani L, Aschard H, et al. How protective are antibodies to SARS-CoV-2, the main weapon of the B-Cell response?. Stem Cell Rev Rep. 2023; 19(3): 585-600. DOI: https://doi.org/10.1007/s12015-022-10477-y
Vanshylla K, Di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, et al. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host Microbe. 2021; 29(6): 917-29.e4. DOI: https://doi.org/10.1016/j.chom.2021.04.015
Mushtaq S, Din NU, Shah AH, Riaz O, Azam K, Khan SW. Association of time-lines of COVID-19 seropositivity with antibody ratio levels. Pak Armed Forces Med J. 2022; 72(3): 1023-26. DOI: https://doi.org/10.51253/pafmj.v72i3.7173
O Murchu E, Byrne P, Walsh KA, Carty PG, Connolly M, De Gascun C, et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review. Rev Med Virol. 2021; 31(2): e2162. DOI: https://doi.org/10.1002/rmv.2162
Röltgen K, Boyd SD. Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host Microbe. 2021; 29(7): 1063-75. DOI: https://doi.org/10.1016/j.chom.2021.06.009
Mushtaq S, Khan A, Khan MMA. Rathore MA, Parveen Bushra, Noor M, et al. Comparison of immune response to SARS-COV-2 vaccine in COVID-recovered versus non-infected Individuals. Clin Exp Med. 2023; 2267–73. DOI: https://doi.org/10.1007/s10238-023-01005-4
Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, et al. Longitudinal analysis shows durable and broad Immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Med Rxiv 2021; 2 (7) : 100354-58. DOI: https://doi.org/10.1101/2021.04.19.21255739
Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing Li, et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat Microbiol. 2022; 7: 423–33.
DOI: https://doi.org/10.1038/s41564-021-01051-2
Gerhards C, Thiaucourt M, Kittel M, Becker C, Ast V, Hetjens M, et al. Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. Int J Infect Dis. 2021; 107: 221-7. DOI: https://doi.org/10.1016/j.ijid.2021.04.080
Chia WN, Zhu F, Ong SW, Young BE, Fong SW, Le Bert N, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: A longitudinal study. Lancet Microbe. 2021; 2(6): e240-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Saadiya Mushtaq
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
